After the introduction of combination antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome, there has been a marked decrease in acquired immunodeficiency syndrome--related morbidity and mortality with a concomitant improvement in the life expectancy of people living with HIV (PLHIV).[@bib1], [@bib2], [@bib3] However, this has been accompanied by a rising incidence of other comorbidities. In particular, cardiovascular disease (CVD) has become a leading cause of death in this population.[@bib4], [@bib5] The shift in the morbidities affecting PLHIV implies that a large portion of their care will be focused on the management of chronic diseases such as CVD.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting 3% to 6% of the general population.[@bib6], [@bib7] The severity and type of symptoms attributed to AF vary significantly ranging from no symptoms to debilitating palpitations, presyncope, syncope, nausea, fatigue, or functional limitation. Furthermore, AF is an important risk factor for stroke, increasing the risk by approximately 5-fold.[@bib8] There are 3 pillars of AF treatment: stroke and systemic thromboembolism (SSE) prophylaxis, prevention of tachycardia-related cardiomyopathy, and symptom improvement.[@bib7]

Although a growing body of literature exists describing CVD in PLHIV,[@bib9], [@bib10], [@bib11] little is known about the impact of HIV infection and ART on SSE prophylaxis in AF. Moreover, it is unclear whether contemporary AF treatment guidelines can be applied to PLHIV because they are predominantly based on clinical trials that exclude this population. The aim of this review is to summarize the current guidelines for the prevention of SSE in AF and describe key considerations for their implementation in PLHIV receiving ART.

Methods {#sec1}
=======

Manuscripts included in this review were systematically identified from searching PubMed and MEDLINE (via PubMed) including the following key Medical Subject Heading terms: "atrial fibrillation," "thromboembolism," "stroke," "warfarin," "dabigatran," "rivaroxaban," "apixaban," and "edoxaban" alone or in combination with the terms "anti-retroviral agents" or "HIV." Our search was focused on English and Spanish language articles published from January 2000 to April 2018.

Results {#sec2}
=======

The literature search yielded 1235 abstracts. Additionally, we included 2 current guidelines on ART and 3 on AF treatment. The initial screening resulted in 112 articles. After reviewing full-text articles, we selected 53 relevant studies pertaining to AF epidemiology and SSE prevention; 22 were focused on the general population, and 31 were focused on PLHIV. The study selection process is described extensively in [Figure 1](#fig1){ref-type="fig"}. Next, we summarize the results of the review according to relevant subheadings. The characteristics of included full-text articles providing data on AF epidemiology and oral anticoagulation (OAC) in PLHIV are shown in [Table 1](#tbl1){ref-type="table"}. [Supplemental Table S1](#appsec1){ref-type="sec"} provides a full-length version of all articles included.Figure 1Flow diagram of the study selection process. AF, atrial fibrillation; ART, antiretroviral therapy; PLHIV, people living with human immunodeficiency virus; SSE, stroke and systemic thromboembolism.Table 1Characteristics of included full-text articles providing data on AF epidemiology and OAC in PLHIVSubjectStudyDesignPopulationMain outcomesSummary of main findingsEpidemiology of AF and SSE in PLHIVSanders[@bib15] (2018)Cohort studyPLHIV and uninfected controlsAFPrevalence of AF in PLHIV: 2%. OR of AF with a nadir CD4 cell count \< 200 cells/mm[@bib3]: 1.98. Comorbidities associated with increased odds of AF: older age, diabetes, hypertension, and chronic obstructive pulmonary disease.Chau[@bib29] (2017)Cohort studyPLHIV with AFSSEHR of SSE by CHA~2~DS~2~-VASc score: 1.70 for score 1 (*P =* 0.28), 1.34 for score ≥ 2 (*P =* 0.55) vs score 0. CHA~2~DS~2~-VASc score did not perform well to predict SSE in PLHIV.Barnes[@bib62] (2017)ReviewPLHIVCVDHigh rates of heart failure, AF, and ischemic stroke in PLHIV. Underlying mechanisms include chronic inflammation and vasculopathy. Pulmonary hypertension continues affecting PLHIV.Adhikari[@bib20] (2016)Cross-sectionalPLHIVVitamin B and folic acid levelsPrevalence of folic acid deficiency up to 32% in PLHIV, highest in individuals with neuropsychiatric symptoms. Prevalence of vitamin B12 deficiency up to 19%.Klein[@bib27] (2016)Cohort studyPLHIVESLDPrevalence of HCV-HIV coinfection = 19%, HBV-HIV = 5% and HCV-HBV-HIV = 2%. ESLD incidence per 1000 person-years was 11.57 in HCV-HBV-HIV infected vs 1.27 in HIV-monoinfected patients. Little use of antivirals for HBV and HCV infection.D'Ascenzo[@bib14] (2015)Meta-analysisPLHIVIschemic strokeIncidence of ischemic stroke: 1.78%. CD4 cell count \< 200 cells/mm[@bib3], HIV-VL, older age, hypertension, smoking, hyperlipidemia, AF, and diabetes were associated with incident stroke.Deminice[@bib18] (2015)Meta-analysisPLHIVLevels of homocysteine, vitamin B12, and folatePLHIV had higher plasma homocysteine and lower folate levels compared with uninfected individuals. PLHIV on ART had higher plasma homocysteine levels compared with PLHIV not on ART.Tsoukas[@bib16] (2014)ReviewPLHIVImmune senescence, atherosclerosisChronic inflammation and the immune risk phenotype are responsible for early aging in PLHIV. In addition to traditional CVD risk factors, this contributes to atherosclerosis development.Hsu[@bib13] (2013)Cohort studyPLHIVAFIncidence of AF: 3.6/1000 person-years. HR of AF: 1.4 for CD4 cell count \< 200 cells/mm^3^ and 1.7 for HIV-VL \> 100,000 copies/mL. Comorbidities associated with incident AF: older age, white race, CAD, heart failure, alcoholism, kidney disease, and hypothyroidism.Elnahar[@bib63] (2012)Case-controlPLHIVRisk factors for AFOR of AF for CD4 cell count \< 250 cells/mm[@bib3]: 3.62 (*P =* 0.017).Franco Moreno[@bib64] (2012)Case seriesPLHIVVTEIncidence of VTE: 3.5%. Pulmonary embolism was the most frequent form (42.9%). Altered thrombophilia tests results in 71.4% of cases.Hepburn[@bib19] (2004)Cohort studyPLHIVVitamin B12 levelsPrevalence of low vitamin 12 levels: 13%. Significant increment in vitamin B12 levels after ART initiation.Contemporary ARTDHHS[@bib41] (2018)GuidelinesPLHIVUse of ARTART is recommended for all PLHIV, based on 2 NRTI plus an INSTI for most PLHIV. Different regimens may be needed in certain clinical situations. ART goals include to maintain a suppressed HIV-VL and prevent HIV transmission.World Health Organization[@bib42] (2016)PLHIVHIV infection treatment and preventionHIV testing should be offered for all people. All PLHIV should be provided with ART. Fixed-dosed tenofovir disoproxil fumarate/lamivudine (or emtricitabine)/efavirenz is the preferred option for ART initiation. Consider pre-exposure prophylaxis for people at substantial risk of HIV infection.Use of warfarin with ARTKumar[@bib54] (2017)Clinical drug interaction studyHealthy volunteersDrug interactionsRitonavir administrated 2 h after dabigatran decreased dabigatran exposure without significant changes in thrombin time. Cobicistat increased dabigatran exposure and thrombin time measures when given simultaneously and separately from dabigatran. Close clinical monitoring is suggested when coadministered with cobicistat.Pelufo-Pellicer[@bib52] (2017)Case reportPLHIVBleeding, drug interactionsBleeding event after switching ART from LPV/r to dolutegravir, probably due to the displacement of warfarin albumin-binding by dolutegravir or interruption of LPV/r CYP2C9 inhibition.Good[@bib51] (2015)Case reportPLHIVINR, drug interactions60% higher dose of warfarin required when coadministered with elvitegravir, probably due to elvitegravir CYP2C9 induction.Liedtke[@bib46] (2012)Case reportPLHIVINR, drug interactions45% (*P* \< 0.001) increase in the mean weekly warfarin dose when switching ART to etravirine, raltegravir, and darunavir/ritonavir, probably due to ritonavir CYP2C9 induction.Honda[@bib50] (2012)Case seriesPLHIVINR, drug interactionsInitiation of raltegravir in patients receiving warfarin was safe. Modifications in warfarin were not necessary. Etravirine can induce CYP3A4 and inhibit CYP2C9 and CYP2C19, potentially interacting with warfarin therapy.Anderson[@bib44] (2012)Cohort studyPLHIV on warfarin therapyINR, drug interactionsLow proportion (34.5%) of therapeutic INR among adherent patients. Injection drug use was an independent risk factor for subtherapeutic INR; 50% higher dose of warfarin required in patients on ritonavir vs efavirenz.Manji[@bib43] (2011)Cohort studyPatients on OACTTRPLHIV represented 25% of study population. HIV infection was associated with lower TTR (47%, *P =* 0.02). ART was not related with TTR.Fulco[@bib45] (2008)Case reportPLHIV on warfarinINR, drug interactionsIncreased warfarin doses required due to induction of CYP3A4 by nevirapine, CYP2C9 by nelfinavir, or CYP2C9 by LPV/r therapy. Close monitoring of INR in patients receiving warfarin with concomitant ART may be necessary.Dionisio[@bib47] (2001)Case seriesPLHIVINR, drug interactionsIncreased warfarin doses required, probably due to nevirapine induction of CYP P450.Use of DOACs with ARTYoong[@bib57] (2017)Case reportPLHIVBleeding, drug interactionsExtensive bruising and high rivaroxaban plasma level when coadministered with elvitegravir/cobicistat, probably due to inhibition of rivaroxaban metabolism by cobicistat. Warfarin therapy may be safer when cobicistat is included in the ART regimen.Perram[@bib59] (2015)Case reportPLHIVDrug interactionsDabigatran is a suitable anticoagulant for PLHIV receiving ritonavir-boosted atazanavir. Monitoring of dabigatran through levels can be useful in this setting.Corallo[@bib56] (2015)Case reportPLHIVBleeding, drug interactionsSurgical site bleeding, prolonged prothrombin time, and high rivaroxaban plasma level when coadministered with darunavir/ritonavir, probably due to CYP3A4 inhibition. Concomitant use of rivaroxaban with darunavir/ritonavir should be avoided.Lakatos[@bib55] (2014)Case reportPLHIVBleeding, drug interactionsGastrointestinal bleeding and high rivaroxaban plasma level when coadministered with darunavir/ritonavir, probably due to inhibition of CYP3A4, CYP2J2, P-gp, and BCRP.Barco[@bib58] (2014)Case reportPLHIVDrug interactionsTrough levels of dabigatran 110 mg twice daily coadministered with LPV/r were similar to results from the Randomized Evaluation of Long-Term Anticoagulation Therapy trial.Egan[@bib49] (2014)ReviewPLHIV on DOACsDrug interactionsProtease inhibitors or cobicistat may inhibit rivaroxaban and apixaban metabolism. NNRTI possible induce rivaroxaban and apixaban metabolism. No clinically relevant interaction expected with dabigatran. No expected effect on DOACs with INSTI, NRTI, or maraviroc.Mueck[@bib53] (2013)Clinical drug interaction studyHealthy volunteersDrug interactionsA single high dose of ritonavir (600 mg twice daily) increased rivaroxaban exposure by 153%, probably due to CYP3A4, P-glycoprotein, and breast cancer resistance protein inhibition.Bates[@bib60] (2013)Case reportPLHIVVTE, drug interactionsVTE event when rivaroxaban was coadministered with nevirapine probably due to CYP3A4 induction by nevirapine.[^1]

Epidemiology {#sec2.1}
------------

The estimated incidence of AF in the general population ranges from 4 to 30 per 1000 person-years,[@bib12] with a lifetime hazard after age 40 years of approximately 25%.[@bib7] This risk increases in older persons and in the presence of heart failure, structural heart disease, hypertension, alcoholism, thyroid disease, diabetes, obesity, and obstructive sleep apnea.[@bib7]

Among PLHIV, Hsu et al.[@bib13] described an incidence rate of AF of 3.6 per 1000 person-years in a large cohort of PLHIV from the Veteran Affairs HIV Clinical Case Registry. Moreover, a meta-analysis investigating the predictors for stroke in PLHIV reported a prevalence of AF of 3%.[@bib14] Sanders et al.[@bib15] performed the first comparison of AF in PLHIV with uninfected controls, yielding a prevalence of AF of 2% in PLHIV. It is expected that the frequency of AF in this population will increase given its strong association with advanced age and traditional CVD risk factors.[@bib1], [@bib12]

Many of the pathogenic mechanisms predisposing to AF result in abnormalities in the atrial structure or electrophysiology.[@bib7] After adjustment for cardiovascular comorbidities, PLHIV with CD4 cell count \< 200 cells/mm^3^ had between 1.4- and 2-fold higher rates of AF, and those with HIV-RNA viral load \> 100,000 copies/mL had 1.7-fold increased risk of incident AF compared with individuals with higher CD4 cell counts and HIV-RNA viral load \< 500 copies/mL, respectively.[@bib13], [@bib15] Purported mechanisms for this relationship include residual excess inflammation, endothelial dysfunction, and macrophage activation present in PLHIV. These factors lead to accelerated atherosclerosis and early aging despite ART and viral suppression.[@bib13], [@bib15], [@bib16] Moreover, risk factors for AF in the general population were also associated with AF in PLHIV, such as older age, diabetes, hypertension, chronic obstructive pulmonary disease, coronary artery disease, heart failure, alcoholism, hypothyroidism, and kidney disease.[@bib13], [@bib15]

Hyperhomocysteinemia is an additional risk factor for stroke, particularly in patients with AF.[@bib17] Several observational studies found that the mean homocysteine concentration was higher in PLHIV compared with uninfected controls, and among PLHIV, individuals exposed to ART had higher concentrations than those without ART.[@bib18] However, inclusion criteria were heterogeneous regarding ART use, stage of HIV infection, and comorbidities. Although multifactorial, vitamin B12 and folate deficiencies can cause hyperhomocysteinemia, and these deficiencies are frequent among PLHIV, with a prevalence of up to 40% and 32%, respectively.[@bib19], [@bib20] Vitamin B supplementation significantly reduces homocysteine plasma levels and might reduce the risk of stroke.[@bib21] For PLHIV with AF, measurement of homocysteine plasma levels should be performed, and if raised, assessment and supplementation with vitamin B12 or folate might be beneficial for stroke prevention.

SSE risk and prevention {#sec2.2}
-----------------------

The estimated risk of SSE in patients with AF is 4% to 6% per year,[@bib8] which vary depending on the presence of certain comorbidities. The Cardiac failure, Hypertension, Age, Diabetes, Stroke (CHADS~2~) and Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke, Vascular disease, Age 65-74, and female Sex (CHA~2~DS~2~-VASc) scores are commonly used schemas that incorporate the most frequent factors to assess the risk of SSE and guide in a practical decision-making process.[@bib7], [@bib22], [@bib23]

The current guidelines for the treatment of AF from the American College of Cardiology and American Heart Association recommend the use of OAC therapy in patients with a prior transient ischemic attack or stroke or CHA~2~DS~2~-VASc score of 2 or greater in men or 3 or greater in woman.[@bib24] The Canadian Cardiovascular Society (CCS) recommends patients with AF be stratified using the "CCS algorithm" named "CHADS-65." Overall, OAC should be prescribed for the prevention of SSE in patients aged 65 years or older with at least 1 CHADS~2~ factor or in the presence of valvular heart disease.[@bib25]

Assessment for bleeding risk is also crucial when considering OAC in patients with AF given the rate of major bleeding with these drugs is 2 to 4 per 100 patient-years.[@bib25], [@bib26] The Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio (INR) measurements for patients on warfarin, Elderly (\> 65 years), Drugs/alcohol concomitantly (HAS-BLED) estimates bleeding risk before starting anticoagulation.[@bib7], [@bib25] In patients taking OAC, particularly in those with HAS-BLED scores ≥ 3, potential bleeding risk factors should be revised, such as avoidance of nonsteroidal anti-inflammatory drugs/aspirin and alcohol misuse, more strict INR monitoring, careful selection of invasive procedures, and control of hypertension, anemia, or liver disease.[@bib23], [@bib25], [@bib26] With regard to liver function, it is noteworthy that coinfection with hepatitis B or C viruses is considerably prevalent in PLHIV (3%-15% and 10%-30%, respectively).[@bib27], [@bib28] Coinfected patients have accelerated progression to end-stage liver disease and hepatocarcinoma, potentially increasing bleeding risk while on OAC. Specific antiviral therapy for hepatitis C or B viruses should be considered in these patients to prevent deleterious outcomes.[@bib27] [Table 2](#tbl2){ref-type="table"} summarizes CHA~2~DS~2~-VASc and bleeding risk factors frequency in PLHIV and in the general population.Table 2Prevalence of CHA~2~DS~2~-VASc and bleeding risk factors in PLHIVConditionPrevalence in PLHIVPrevalence in general populationCongestive heart failure[∗](#tbl2fnlowast){ref-type="table-fn"}7%[@bib62]5%[@bib62]Hypertension[∗](#tbl2fnlowast){ref-type="table-fn"}[†](#tbl2fndagger){ref-type="table-fn"}33%[@bib15]19%-62%[@bib15]^,^[@bib65]Age ≥ 65 y[∗](#tbl2fnlowast){ref-type="table-fn"}[†](#tbl2fndagger){ref-type="table-fn"}14%[@bib15]14%[@bib15]Diabetes mellitus[∗](#tbl2fnlowast){ref-type="table-fn"}9%[@bib15]6%-9%[@bib15]^,^[@bib65]Stroke/transient ischemic attack/thromboembolism[∗](#tbl2fnlowast){ref-type="table-fn"}[†](#tbl2fndagger){ref-type="table-fn"}1%-6%[@bib15]^,^[@bib64]3%-4%[@bib15]^,^[@bib65]Myocardial infarction[∗](#tbl2fnlowast){ref-type="table-fn"}11%[@bib15]4%-5%[@bib15]^,^[@bib65]Coronary heart disease[∗](#tbl2fnlowast){ref-type="table-fn"}14%[@bib15]7%[@bib15]^,^[@bib65]Abnormal renal function[†](#tbl2fndagger){ref-type="table-fn"}7%-14%[@bib13]4%[@bib65]Abnormal liver function/hepatitis C infection[†](#tbl2fndagger){ref-type="table-fn"}3%-23%[@bib15], [@bib28]1%[@bib15]TTR[†](#tbl2fndagger){ref-type="table-fn"}[‡](#tbl2fnddagger){ref-type="table-fn"}31%-47%[@bib43], [@bib44]56%-70%[@bib32], [@bib36]Alcohol excess[†](#tbl2fndagger){ref-type="table-fn"}7%-35%[@bib13], [@bib28], [@bib30]3%-16%[@bib65][^2][^3][^4][^5]

Stroke is more prevalent in PLHIV than in HIV-negative individuals.[@bib29] Nevertheless, it is unclear whether the presence of HIV infection alters the risk of stroke in individuals with AF. Likewise, the ability of available scores to estimate the need of OAC in PLHIV with AF has been scarcely studied. Chau et al.[@bib29] found a rate of 8.1 SSE events per 1000 person-years in PLHIV with CHA~2~DS~2~-VASc score ≥ 2, lower than expected for the same score in the general population. This may be explained by the lower mean age of PLHIV with AF vs the general population. Moreover, there was not a gradual increment on SSE rate with increasing CHA~2~DS~2~-VASc score, suggesting that it is not well calibrated for PLHIV.[@bib29] HIV-specific factors not considered by the CHA~2~DS~2~-VASc score, such as CD4 cell count, HIV-RNA viral load,[@bib29] and ART, may affect the rate of SSE in PLHIV. Until more evidence is available, it appears reasonable to apply the CCS or American College of Cardiology and American Heart Association guidelines to PLHIV with AF.[@bib24], [@bib25]

OACs used for SSE prophylaxis in AF include vitamin K antagonists (VKAs) (eg, warfarin/Coumadin) or direct oral anticoagulants (DOACs), such as direct thrombin inhibitors (eg, dabigatran) and factor X--activated inhibitors (eg, rivaroxaban, apixaban, edoxaban). VKAs have reduced stroke rates vs aspirin or no treatment by 37% and 64%, respectively, and mortality rate by 26% vs control.[@bib23], [@bib26] Furthermore, widely available reversal agents exist in case of severe bleeding. However, activity of VKAs can be affected by many medications and foods, and requires frequent monitoring of INR to ensure time in therapeutic range (TTR).[@bib7], [@bib30], [@bib31]

The efficacy and safety of DOACs on SSE prophylaxis have been compared with VKAs. In randomized controlled trials, dabigatran 150 mg twice daily and apixaban 5 mg twice daily were superior to warfarin,[@bib32], [@bib33] whereas dabigatran 110 mg twice daily, rivaroxaban 20 mg daily, and edoxaban 30 mg or 60 mg daily were noninferior to warfarin.[@bib32], [@bib34], [@bib35] Furthermore, all DOACs reduced the risk of intracranial haemorrhage compared with VKAs.[@bib32], [@bib33], [@bib34], [@bib35] Observational studies supported these results[@bib31], [@bib36] and reported the comparative effectiveness and safety of DOACs. Overall, dabigatran, rivaroxaban, apixaban, and edoxaban demonstrated similar effectiveness in preventing SSE, whereas rivaroxaban treatment was associated with a higher risk of bleeding.[@bib30], [@bib37], [@bib38], [@bib39], [@bib40] DOACs have a predictable effect and do not require blood testing for anticoagulation monitoring. Currently approved DOAC reversal agents are idarucizumab, a humanized monoclonal antibody for reversal of dabigatran, and andexanet alfa, a recombinant factor Xa without intrinsic catalytic activity for reversal of apixaban and rivaroxaban.[@bib25], [@bib38] Reversal agents should be administrated for major or life-threatening bleeding unresponsive to supportive measures or before urgent procedures associated with high bleeding risk.[@bib25] There is lack of evidence on the administration of DOAC reversal agents with ART or in PLHIV.

Contemporary ART {#sec2.3}
----------------

ART has dramatically altered the natural history of HIV infection averting associated morbidity, mortality, and transmission.[@bib41] There are sufficient data to offer ART to all PLHIV irrespective of CD4 cell count to achieve utmost and sustained HIV-RNA viral load suppression.[@bib41], [@bib42] Availability of new treatment options modifies therapeutic preferences periodically. Current World Health Organization antiretroviral guidelines recommend first-line regimens consisting of 2 nucleoside reverse transcriptase inhibitors (NRTI) (tenofovir disoproxil fumarate plus emtricitabine or lamivudine) in addition to a non-nucleoside reverse transcriptase inhibitor (NNRTI) (efavirenz) or an integrase strand transfer inhibitor (INSTI) (dolutegravir), prioritizing fixed-dose combinations.[@bib42]

The US Department of Health and Human Services antiretroviral guidelines recommend an initial regimen based on a combination of 2 NRTIs (tenofovir disoproxil fumarate, tenofovir alafenamide, or abacavir plus lamivudine or emtricitabine) and a third active drug from the INSTI family (bictegravir, dolutegravir, or raltegravir) for most PLHIV. Pharmacologically enhanced protease inhibitors (PIs), elvitegravir/cobicistat, and NNRTIs are recommended as third drugs in certain clinical scenarios.[@bib41] Specific factors such as viral resistance, comorbidities, toxicity, drug interactions, and adherence can determine alternative first-line regimens.[@bib41]

Antithrombotic therapy in PLHIV {#sec2.4}
-------------------------------

Current AF guidelines pertaining to antithrombotic therapy do not assess PLHIV as a special population,[@bib24], [@bib25] and PLHIV are typically excluded from clinical trials evaluating OAC. Therefore, knowledge of antithrombotic therapy in PLHIV stems from observational studies and clinical drug-interaction studies in healthy volunteers. Only 1 article assessed OAC effectiveness for SSE prevention in PLHIV with AF.[@bib29] In this study, warfarin was not protective for SSE events.[@bib29] Although the reason for this challenging finding requires further inquiry, it is suspected to be related to an increased thrombogenic state, diverse stroke etiologies, and difficulties in attaining appropriate warfarin therapy among PLHIV.

Use of warfarin with antiretrovirals {#sec2.5}
------------------------------------

The risk of stroke or bleeding with warfarin therapy directly correlates to the proportion of time within the INR TTR. PLHIV have a substantially lower TTR compared with the general population.[@bib43] Cohort studies have shown that the TTR for PLHIV on warfarin therapy was only 47%[@bib43] vs 56% to 70%[@bib31], [@bib36] in the general population. In those with INR outside the target, 50% had subtherapeutic INR and 17% had supratherapeutic INR.[@bib44] A subtherapeutic INR exposes the patient to an increased risk of stroke, whereas a supratherapeutic INR increases the bleeding hazard.

Difficulty to attain TTR may be caused by drug--drug interactions and unreported nonadherence. Drug--drug interactions are primarily a result of alterations in warfarin metabolism through increases or decreases in cytochrome P450 (CYP) 2C9 enzyme activity.[@bib45] Warfarin dose requirements substantially increase in patients receiving boosted PI and nevirapine, an NNRTI, due to CYP2C9 induction.[@bib45], [@bib46], [@bib47] On the other hand, efavirenz was associated with warfarin overdosing and bleeding due to CYP2C9 inhibition.[@bib44], [@bib48] This inhibition of warfarin metabolism can theoretically occur with etravirine, a weak CYP2C9 inhibitor,[@bib48] contributing to the INR variability shown by Liedtke et al.[@bib46] Warfarin is not expected to interact with NRTI[@bib49] or maraviroc, a drug that antagonizes C-C chemokine receptor type 5 averting infection of the cell by HIV.[@bib48], [@bib49]

Among INSTI, elvitegravir is the only drug that influences CYP450 isoenzymes by inducing the CYP2C9 activity.[@bib49], [@bib50], [@bib51] Because it is coformulated with cobicistat (a pharmacokinetic enhancer without antiviral activity that is a strong CYP3A4 inhibitor with no effect on CYP2C9), mild opposite effects might be seen. Only 1 case reported by Good et al.[@bib51] showed that increased warfarin dosages were necessary when coadministered with elvitegravir/cobicistat, suggesting that CYP2C9 induction by elvitegravir was predominant. Conversely, raltegravir can be safely used with warfarin, as described by Honda et al.[@bib50] Recently, a case of a woman who presented with haemorrhages after switching from lopinavir/ritonavir (LPV/r) to dolutegravir was reported. The reason for this bleeding event may have been the displacement of warfarin albumin-binding by dolutegravir or the end in warfarin metabolism induction after stopping LPV/r.[@bib52] So far, no data have been reported on the coadministration of bictegravir and warfarin. More frequent monitoring of INR is prudent in PLHIV who are on warfarin and have any ART regimen modification.

Use of DOACs with antiretrovirals {#sec2.6}
---------------------------------

DOACs are metabolized by CYP3A4 and P-glycoprotein transporter (P-gp) with the exception of dabigatran and edoxaban, which are mainly substrates for P-gp.[@bib35], [@bib49] Next, we discuss pertinent issues of using DOACs with specific antiretroviral agents or drug classes.

Protease inhibitors and cobicistat {#sec2.7}
----------------------------------

The anticoagulant effect of factor X--activated inhibitors is potentiated when coadministered with strong inhibitors of CYP3A4 and P-gp such as ritonavir[@bib53] or cobicistat,[@bib54] potentially leading to bleeding events. With the exception of tipranavir, other PIs are inhibitors to a lesser extent.[@bib49] Evidence of rivaroxaban interacting with PI has been demonstrated. Mueck et al.[@bib53] showed a significant increase in rivaroxaban exposure after ritonavir administration in healthy volunteers. Lakatos et al.[@bib55] and Corallo et al.[@bib56] reported bleeding events related to ritonavir-boosted darunavir and rivaroxaban coadministration. Regarding cobicistat, Yoong et al.[@bib57] described a case of extensive bruising after rivaroxaban introduction in a patient with AF. Although no published data are available on the interaction between other factor X--activated inhibitors and PI or cobicistat, it is recommended to avoid their use concomitantly.[@bib41]

Because of the unique metabolism of dabigatran among DOACs, it can be coadministered with much current ART. Among PIs, Kumar et al.[@bib54] found no significant interactions when dabigatran was simultaneously taken with ritonavir in healthy subjects despite being a potent P-gp inhibitor. Barco et al.[@bib58] described favourable outcomes with LPV/r and full-dosed dabigatran in a person living with HIV requiring dabigatran peri-AF ablation. Likewise, Perram et al.[@bib59] revealed the successful combination of ritonavir-boosted atazanavir with dabigatran. Conversely, it has been shown that simultaneous cobicistat administration significantly increased dabigatran anticoagulant effect by 51% in healthy volunteers.[@bib54] To minimize the impact of cobicistat, the authors suggested closely monitoring of dabigatran anticoagulant effect, reduced dabigatran dosing (eg, 75 mg twice daily), separate dosing by at least 4 hours, or monitoring of DOAC levels.[@bib54] Therefore, consider avoiding this association in view of its challenging management.[@bib41]

Non-nucleoside reverse transcriptase inhibitors {#sec2.8}
-----------------------------------------------

The NNRTIs nevirapine, efavirenz, and etravirine share the capacity to induce CYP3A4 potentially leading to the loss of anticoagulant effect of DOACs metabolized that way.[@bib41], [@bib49], [@bib55] Accordingly, Bates et al.[@bib60] reported a case in which concurrent nevirapine may have increased the clearance of rivaroxaban, leading to deep venous thrombosis with pulmonary embolism. Weak P-gp inhibitors such as etravirine[@bib41] and rilpivirine[@bib61] might potentiate the anticoagulant effect of DOACs even though no bleeding events were reported. Because efavirenz or nevirapine do not appreciably affect P-gp, their coadministration with dabigatran and edoxaban is likely to be safe.[@bib41] So far, no data regarding the administration of the novel NNRTI, doravirine, with DOACs have been reported. However, given the lack of induction/inhibition of CYP450 isoenzymes or P-gp by this drug, no significant interactions are expected.

Integrase strand transfer inhibitors {#sec2.9}
------------------------------------

Although not extensively studied, there are no expected interactions between INSTIs and DOACs. However, elvitegravir must be coadministered with a pharmacokinetic booster (cobicistat or ritonavir) to achieve appropriate plasma levels. Therefore, this combination is generally not recommended when prescribing DOACs.[@bib41], [@bib49]

Other antiretrovirals {#sec2.10}
---------------------

NRTIs and maraviroc do not affect DOAC metabolism and can be used concomitantly without expected interactions.[@bib49] It is recommended to avoid factor X--activated inhibitors (rivaroxaban, apixaban) in combination with cobicistat, PIs, or NNRTIs.[@bib41], [@bib55] The direct thrombin inhibitor dabigatran can be prudently administrated with ritonavir-boosted PIs and NNRTIs. [Figure 2](#fig2){ref-type="fig"} summarizes possible drug--drug interactions.Figure 2Drug interactions between oral anticoagulants and antiretrovirals. ↓ = ART decreases OAC concentration; ↑ = ART increases OAC concentration. \*Potentially solved by increasing INR monitoring. \*\*Coadministrate simultaneously. ART, antiretroviral therapy; CCR5, C-C chemokine receptor type 5; FTC, emtricitabine; INR, international normalized ratio; OAC, oral anticoagulant; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. Data sources: References[@bib41], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60].

Conclusions {#sec3}
===========

The focus of HIV-related care has changed substantially over the past decades, with CVD becoming an increasingly prominent cause of death in PLHIV. Although AF risk factors are prevalent in PLHIV, there are limited data regarding AF outcomes and management in this population. Moreover, stroke prediction scores commonly used in the general population, such as the CHA~2~DS~2~-VASc, have low accuracy in PLHIV. Until additional literature regarding AF in PLHIV becomes available, the guidelines developed for the general population should be followed with some considerations. PLHIV with AF should have a comprehensive evaluation that includes SSE risk estimation, bearing in mind the lack of validation of available scores in this population. OACs should be prescribed when appropriate, taking into account potential drug--drug interactions. Further research is needed to advance this understanding and define the best approach for AF management in PLHIV.
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[^1]: AF, atrial fibrillation; ART, antiretroviral therapy; CAD, coronary artery disease; CHADS~2~, cardiac failure, hypertension, age, diabetes, stroke; CHA~2~DS~2~-VASc, congestive heart failure, hypertension, age ≥75,diabetes, stroke, vascular disease, age 65-74, and female sex; CVD, cardiovascular disease; CYP, cytochrome; DOACs, direct oral anticoagulants; ESLD, end-stage liver disease; HIV-VL, HIV-RNA viral load; HR, hazard ratio; INR, international normalized ratio; INSTI, integrase strand transfer inhibitors; LPV/r, lopinavir/ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitors; NVAF, nonvalvular atrial fibrillation; OAC, oral anticoagulation; OR, odds ratio; PLHIV, people living with human immunodeficiency virus; SSE, stroke and systemic thromboembolism; TTR, time in therapeutic range; VTE, venous thromboembolism.

[^2]: INR, international normalized ratio; CHA~2~DS~2~-VASc, congestive heart failure, hypertension, age ≥75, diabetes, stroke, vascular disease, age 65-74, and female sex; PLHIV, people living with HIV; TTR, time in therapeutic range.

[^3]: Risk factor for stroke.

[^4]: Risk factor for bleeding.

[^5]: TTR \< 60% is considered as labile INR.
